BioSpace News Archive

NexGard® and NexGard Spectra™ receives Health Canada approval for the reduction of Borrelia burgdorferi (B. burgdorferi) infections as a direct result of killing adult Ixodes scapularis (I. scapularis) vector ticks. B. burgdorferi is the causative agent of Lyme disease.

Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int’l., Inc., announces that the U.S. Food and Drug Administration has granted its application for Fast Track designation of seviprotimut-L, its melanoma cancer vaccine for the adjuvant treatment of stage IIB/IIC melanoma patients post-resection to improve recurrence-free survival.

The Lung Cancer Registry has launched a landmark new survey on the impact of lung treatments on women’s sexual health.

Agreement centers on identifying HER2 gene mutations using Oncomine Dx Target Test

Hard surface disinfectant formulations with Glyclean™AM as the active ingredient effectively kill SARS-CoV-2, the virus that causes COVID-19.

Glassbeam, Inc., the premier machine data analytics company, announced it has expanded its OEM partner ecosystem to include Siemens Healthineers, a leading medical technology company, in its Strategic Reseller program to amplify the access and penetration of Glassbeam Clinsights™ offerings in the healthcare industry.

Schrödinger announced a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery.

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced a significant expansion of its work to discover novel antiviral therapeutics for COVID-19 as a part of a philanthropic global initiative.

Century Therapeutics Canada will develop induced pluripotent Stem Cell (iPSC)-derived allogeneic immune cell therapies against glioblastoma (GBM)

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The decision was made after assessing the totality of the data including the 500 mg cohort, the highest dose studied in the trial. “Alth